Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117237) titled 'High-Dose Romiplostim (N01) Monotherapy for Aplastic Anemia with Specific Gene Mutations: A Prospective Clinical Study' on Jan. 21.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University
Condition:
aplastic anemia
Intervention:
Study Group: Receive high-dose Ropylstim N01 monotherapy (20 µg/kg, subcutaneously once weekly).
Concurrent Control Group 1 : Receive high-dose Ropylstim N01 monotherapy (20 µg/kg, subcutaneously once weekly)
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enr...